A randomized, double blind, controlled, parallel clinical trial to assess the Efficacy and Safety of Liposomal vitamin C compared with Vitamin C (non liposomal) on Immunity, inflammation and metabolic markers in adult subjects with alcohol consumption, smoking and common metabolic abnormalities.

CureSupport0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. 18 years of age and above
•2. Metabolic abnormalities with or without alcohol consumption and/or smoking
•3. Diagnosis of MetS ie. the presence of three or more criteria of the modified National Cholesterol Education Programs Adult Treatment Panel III ( NCEP ATP III:
•3.1 Waist circumference 90 cm in men and 80 cm in women
•3.2 Hypertriglyceridemia >= 150 mg/dl
•3.3 High density lipoprotein (HDL) cholesterol 40 mg/dl in males and 50 mg/dl in females
•3.4 Blood pressure >= 130/85 mm Hg
•3.5 Fasting plasma glucose >= 110 mg/dl
•3.6 Patients willing to provide written informed consent

•1. Acute illness within the past 2 weeks
•2. Pregnancy or breastfeeding
•3. Lack of compliance with the study medication (defined as not using the medication for >1 week)
•4. Documented intolerability to vitamin C
•5. Participation in a concomitant trial
•6. Hypersensitivity to the study medication
•7. Regularly used nonsteroidal anti-inflammatory drugs (naproxen and cyclooxygenase-2 inhibitors) and/or cholesterol-lowering agents (statins)
•8. Suffered from systemic and inflammatory diseases that change physical or laboratory tests (arthritis, renal, thyroid, hepatic, respiratory, gout, active malignant disease)
•9. Impossibility to give informed consent
•10. Intake of drugs or dietary supplements
•11. Previous illnesses such as heart attack, cancer or dementia
•12. Addiction illness

发起方

CureSupport